SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Rhea-AI Summary

SciSparc Ltd. (Nasdaq: SPRC) and Clearmind Medicine have filed an international patent application for a novel combination therapy using MEAI and PEA compounds, targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

The therapy combines 5-methoxy-2-aminoindane with N-Acylethanolamines (MEAI) and Palmitoylethanolamide (PEA) to address global health challenges affecting over 890 million people with obesity and 30% of the global adult population with non-alcoholic fatty liver disease (NAFLD). This development expands their existing patent portfolio across multiple jurisdictions.

Positive

• Filing of international patent application strengthens intellectual property portfolio
• Addresses two major global health markets: obesity (890M people) and NAFLD (30% of global adults)
• Potential to offer new treatment option in markets with limited therapeutic alternatives

Negative

• Early-stage development with no clinical efficacy data presented
• Patent application filing does not guarantee approval or commercial success

Insights

Pharmaceutical Industry Analyst

SciSparc's patent application for MEAI-PEA combination therapy addresses massive obesity and liver disease markets with significant commercial potential.

SciSparc's collaboration with Clearmind Medicine has yielded a potentially valuable patent application for a novel combination therapy. The filing covers a proprietary formulation combining 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), targeting two substantial global health markets: obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

This patent application represents a strategic move to establish intellectual property protection in these lucrative therapeutic areas. The obesity market presents an enormous opportunity, with 890+ million affected individuals globally according to WHO data cited in the release. Similarly, non-alcoholic fatty liver disease (NAFLD) affects approximately 30% of the global adult population, creating another substantial addressable market.

The combined approach leverages MEAI's pharmacological profile alongside PEA's established anti-inflammatory and neuroprotective properties. This dual-mechanism strategy is particularly noteworthy as both conditions often co-exist and share metabolic dysfunction pathways. Current treatment options remain limited for both conditions, creating a significant unmet medical need.

This international PCT filing builds upon previous patent applications in the US and other territories, demonstrating a comprehensive IP strategy. While still in early stages without disclosed clinical data, securing robust patent protection now establishes potential barriers to competition and creates future licensing opportunities. The ongoing collaboration between these two companies suggests a shared development approach that may optimize resources while pursuing these challenging but potentially lucrative therapeutic areas.

TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the filing of a new international patent application under the Patent Cooperation Treaty. The application covers its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) and Palmitoylethanolamide (PEA).

This proprietary combination is designed to address two significant global health challenges: obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). According to the World Health Organization, obesity affects over 890 million people worldwide and is a leading risk factor for a range of chronic conditions. Meanwhile, non-alcoholic fatty liver disease (NAFLD), which is closely linked to metabolic disorders and poor long-term outcomes, is estimated to impact more than 30% of the global adult population, according to the article titled “Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons,” published in August 2023. Despite the scale of these problems, treatment options remain limited.

According to Clearmind, the novel approach has the potential to offer a safe and effective therapeutic alternative, leveraging the unique pharmacological profile of MEAI alongside the anti-inflammatory and neuroprotective properties of PEA.

This latest development adds to multiple patent applications already filed in the U.S. and other countries as part of the ongoing SciSparc-Clearmind collaboration.

About SciSparc Ltd. (Nasdaq: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.

About Clearmind Medicine Inc. (Nasdaq: CMND) (FSE: CWY)

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Clearmind’s intellectual portfolio currently consists of 19 patent families including 31 granted patents. For further information visit: https://www.clearmindmedicine.com

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing the potential benefits and advantages of the new patent application, that this proprietary combination is designed to address two significant global health challenges: obesity and MASLD, and that it has the potential to offer a safe and effective therapeutic alternative, leveraging the unique pharmacological profile of MEAI alongside the anti-inflammatory and neuroprotective properties of PEA. Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

FAQ

What is the new patent application filed by SciSparc (SPRC) and Clearmind about?

The patent application covers a novel combination therapy using MEAI and PEA compounds, designed to treat obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

What is the market size for SciSparc's (SPRC) new obesity and liver disease treatment?

The treatment targets a significant market with over 890 million people affected by obesity worldwide and more than 30% of global adults affected by non-alcoholic fatty liver disease.

What compounds are included in SciSparc's (SPRC) new combination therapy?

The therapy combines 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) with Palmitoylethanolamide (PEA).

How does SciSparc's (SPRC) patent application strengthen their business?

The international patent application enhances their intellectual property portfolio and adds to multiple existing patent applications filed in the U.S. and other countries through their Clearmind collaboration.

What medical conditions does SciSparc's (SPRC) new therapy target?

The therapy targets two major health challenges: obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), also known as non-alcoholic fatty liver disease (NAFLD).